Korro Bio downgraded by RBC Capital Mkts with a new price target
$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts downgraded Korro Bio from Outperform to Sector Perform and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2025 | $8.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 11/13/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/13/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/13/2025 | $7.00 | Buy → Neutral | Chardan Capital Markets |
| 11/13/2025 | Outperform → Mkt Perform | William Blair | |
| 11/13/2025 | Strong Buy → Mkt Perform | Raymond James | |
| 11/13/2025 | $11.00 | Overweight → Neutral | Piper Sandler |
| 4/29/2025 | $74.00 | Overweight | Cantor Fitzgerald |
RBC Capital Mkts downgraded Korro Bio from Outperform to Sector Perform and set a new price target of $8.00
Cantor Fitzgerald downgraded Korro Bio from Overweight to Neutral
H.C. Wainwright downgraded Korro Bio from Buy to Neutral
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th
- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro's website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days. About Korro Korro is a biop
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients —KRRO-110 did not reach projected levels of functional protein following a single administration —Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026 —Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia —Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by impleme
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's 2025 Biopharma Back to School ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025. Cantor Global Healthcare ConferenceDr. Aiyar will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 p.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the
8-K - Korro Bio, Inc. (0001703647) (Filer)
SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)
10-Q - Korro Bio, Inc. (0001703647) (Filer)